Search research articles
Contact Us
Filters
Showing results (71-80 of 201) with videos related to
Page
of 21
Sort By:
Acta Paediatrica (Oslo, Norway : 1992)
|
June 1, 2007
Kostmann syndrome or infantile genetic agranulocytosis, part two: Understanding the underlying genetic defects in severe congenital neutropenia
Göran Carlsson, Malin Melin, Niklas Dahl, et al.
Pediatric Blood & Cancer
|
August 19, 2009
Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis
Désirée Gavhed, Selma Olsson Akefeldt, Gustaf Osterlundh, et al.
Molecular Immunology
|
June 15, 2010
The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells
Xiaoli Feng, Jie Yan, Yibiao Wang, et al.
Journal of Periodontology
|
April 6, 2006
Periodontal disease in patients from the original Kostmann family with severe congenital neutropenia
Göran Carlsson, Ylva-Britt Wahlin, Anders Johansson, et al.
Frontiers in Pediatrics
|
July 18, 2022
Plasma Signaling Factors in Patients With Langerhans Cell Histiocytosis (LCH) Correlate With Relative Frequencies of LCH Cells and T Cells Within Lesions
Jenée Mitchell, Egle Kvedaraite, Tatiana von Bahr Greenwood, et al.
British Journal of Haematology
|
May 26, 2012
Incidence of severe congenital neutropenia in Sweden and risk of evolution to myelodysplastic syndrome/leukaemia
Göran Carlsson, Anders Fasth, Elisabet Berglöf, et al.
Cytokine
|
October 20, 2019
High levels of plasma interleukin-17A are associated with severe neurological sequelae in Langerhans cell histiocytosis
Mohamad Bachar Ismail, Selma Olsson Åkefeldt, Magda Lourda, et al.
Experimental Cell Research
|
April 1, 2014
Pathophysiology and spectrum of diseases caused by defects in lymphocyte cytotoxicity
Marie Meeths, Samuel C C Chiang, Alexandra Löfstedt, et al.
Anti-Cancer Drugs
|
December 5, 2013
Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells
Xiangling Wang, Xiaoli Feng, Juandong Wang, et al.
Pediatric Blood & Cancer
|
October 22, 2008
Treatment of the X-linked lymphoproliferative, Griscelli and Chédiak-Higashi syndromes by HLH directed therapy
Helena Trottestam, Karin Beutel, Marie Meeths, et al.
Page
of 21
Search research articles
Search
Showing results (71-80 of 201) with videos related to
Sort By:
Page
of 21
Acta Paediatrica (Oslo, Norway : 1992)
|
June 1, 2007
Kostmann syndrome or infantile genetic agranulocytosis, part two: Understanding the underlying genetic defects in severe congenital neutropenia
Göran Carlsson, Malin Melin, Niklas Dahl, et al.
Pediatric Blood & Cancer
|
August 19, 2009
Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis
Désirée Gavhed, Selma Olsson Akefeldt, Gustaf Osterlundh, et al.
Molecular Immunology
|
June 15, 2010
The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells
Xiaoli Feng, Jie Yan, Yibiao Wang, et al.
Journal of Periodontology
|
April 6, 2006
Periodontal disease in patients from the original Kostmann family with severe congenital neutropenia
Göran Carlsson, Ylva-Britt Wahlin, Anders Johansson, et al.
Frontiers in Pediatrics
|
July 18, 2022
Plasma Signaling Factors in Patients With Langerhans Cell Histiocytosis (LCH) Correlate With Relative Frequencies of LCH Cells and T Cells Within Lesions
Jenée Mitchell, Egle Kvedaraite, Tatiana von Bahr Greenwood, et al.
British Journal of Haematology
|
May 26, 2012
Incidence of severe congenital neutropenia in Sweden and risk of evolution to myelodysplastic syndrome/leukaemia
Göran Carlsson, Anders Fasth, Elisabet Berglöf, et al.
Cytokine
|
October 20, 2019
High levels of plasma interleukin-17A are associated with severe neurological sequelae in Langerhans cell histiocytosis
Mohamad Bachar Ismail, Selma Olsson Åkefeldt, Magda Lourda, et al.
Experimental Cell Research
|
April 1, 2014
Pathophysiology and spectrum of diseases caused by defects in lymphocyte cytotoxicity
Marie Meeths, Samuel C C Chiang, Alexandra Löfstedt, et al.
Anti-Cancer Drugs
|
December 5, 2013
Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells
Xiangling Wang, Xiaoli Feng, Juandong Wang, et al.
Pediatric Blood & Cancer
|
October 22, 2008
Treatment of the X-linked lymphoproliferative, Griscelli and Chédiak-Higashi syndromes by HLH directed therapy
Helena Trottestam, Karin Beutel, Marie Meeths, et al.
Page
of 21